Eric M. Horwitz, MD, FABS, FASTRO

E Horwitz 2024

Request an Appointment

Clinical Locations

  • Fox Chase Cancer Center
    333 Cottman Avenue
    Philadelphia, PA 19111
    Phone: 888-369-2427
  • Fox Chase - Buckingham
    2365 Heritage Center Drive
    Furlong, PA 18925
    Phone: 888-369-2427
  • Fox Chase Cancer Center - Voorhees
    502 Centennial Blvd
    Suite 7
    Voorhees, NJ 08043
    Phone: 888-369-2427

Chair, Department of Radiation Oncology, Lewis Katz School of Medicine at Temple University

Chair, Department of Radiation Oncology, Fox Chase Cancer Center

Professor

Gerald E. Hanks Endowed Chair in Radiation Oncology

NCCN, Prostate Cancer Panel Member

Specialties

  • Genitourinary Radiation Oncology
  • Radiation Oncology

Areas of Expertise

Urethral Cancer, Penile Cancer, Ureteral Cancer, Kidney Cancer, Testicular Cancer, Bladder Cancer, Prostate Cancer

Treatment Focus

  • Intensity Modulated Radiation Therapy (IMRT)
  • Stereotactic body Radiation Therapy (SBRT)
  • HDR temporary prostate brachytherapy
  • LDR permanent prostate brachytherapy

Distinctions

Treatment Philosophy

In addition to my focus on treating and caring for patients with prostate and bladder cancer, it is my responsibility as Chairman of the Department of Radiation Oncology at Fox Chase; an NCI designated National Comprehensive Cancer Center to promote the mission of the Center to prevail over cancer. Our department's expertise has always focused on developing and integrating sophisticated technology into successful treatment for our cancer patients and I remain committed to continuing and expanding this legacy. However, the successful treatment of a patient is not just based on the technology that is available. Being diagnosed with cancer and receiving treatment is one of the most difficult things that many people will ever face, and it is crucial that we as caregivers do not forget this. Caring for patients as one important part of a multidisciplinary team allows us in the Department of Radiation Oncology to provide the best possible care for our patients.

Chair, Radiation Oncology

Since joining the staff in 1997, Dr. Horwitz's contributions include spearheading the clinical program as it grew exponentially in size and patient volumes. He developed advanced treatment programs using intensity-modulated radiation therapy (IMRT), image-guided radiation therapy and brachytherapy, including high-dose-rate (HDR) brachytherapy for prostate cancer and CT based adaptive radiation therapy. As a result, Fox Chase was the first in the eastern United States to offer HDR implants to men with prostate cancer. .

In addition, Dr. Horwitz integrated the use of an MRI treatment simulator into prostate cancer treatment planning for both permanent, low-dose prostate implants and external radiation therapy. Fox Chase was the first in the world to use MRI in radiation treatment planning.

Dr. Horwitz has published extensively in peer-reviewed journals and is a co-author of multiple chapters in various oncology texts. He has been invited to give numerous lectures and presentations at professional meetings in the United States and abroad. Dr. Horwitz has been named a top doctor by Castle Connolly's "American's Top Doctors" and is annually listed as one of Philadelphia magazine's "Top Docs."

He serves on the editorial board of the journal Brachytherapy and is the past-President and Chairman of the Board of the American Brachytherapy Society. He is also active in the American Society of Radiation Oncology and the American Board of Radiology.

Dr. Horwitz received his MD from Albany Medical College in New York after earning his undergraduate degree at the University of Pennsylvania in Philadelphia. He completed both his internship and residency at William Beaumont Hospital in Royal Oak, Mich., where he was chief resident in radiation oncology. Dr. Horwitz joined Fox Chase in 1997. Since 2008, he has been the Chair of the Department of Radiation Oncology at Fox Chase. In 2009, he was promoted from Associate Professor to Professor and holder of the Gerald E. Hanks Chair in Radiation Oncology with tenure in Fox Chase's division of medical science. In 2022, he led the integration of the Department of Radiation Oncology across the Temple University Health System and now leads the single radiation oncology department at Fox Chase and the Lewis Katz School of Medicine at Temple University.

Educational Background

  • Resident, Radiation Oncology, William Beaumont Hospital, Royal Oak, MI
  • MD, Albany Medical College, Albany, NY, 1992
  • BA, History, Chemistry minor, University of Pennsylvania, Philadelphia, PA, 1988

Certifications

  • American Board of Radiology - Radiation Oncology

Memberships

  • National Comprehensive Cancer Network (NCCN)
    • Prostate Cancer Panel
  • American Society of Radiation Oncology (ASTRO)
  • American Brachytherapy Society (ABS)
  • American Board of Radiology (ABR)
  • American Medical Association (AMA)

Honors & Awards

  • Volunteer Service Award, American Board of Radiology, 2014, 2022-2024
  • Philadelphia Magazine Top Doctors, 2002, 2005-2024
  • Best Doctors in America® , 2013-14, 2019-2020, Radiation Oncology
  • Inaugural Fellow, American Brachytherapy Society (ABS), 2017
  • America’s Top Doctors®, 2015-17
  • Newsweek Top Cancer Doctors, 2015
  • Distinguished Service Award, American Brachytherapy Society, 2010

Research Interests

  • Determining outcomes in treatment for prostate cancer patients treated with external beam radiation and brachytherapy
  • Developing image guidance techniques for prostate cancer radiation
  • Developing new bladder preservation techniques to treat patients with muscle invasive bladder cancer

Selected Publications

Shulman R.M., Weinberg D.S., Ross E.A., Ruth K., Rall G.F., Olszanski A.J., Helstrom J., Hall M.J., Judd J., Chen D.Y.T., Uzzo R.G., Dougherty T.P., Williams R., Geynisman D.M., Fang C.Y., Fisher R.I., Strother M., Huelsmann E., Adige S., Whooley P.D., Zarrabi K., Gupta B., Iyer P., McShane M., Yankey H., Lee C.T., Burbure N., Laderman L.E., Giurintano J., Reiss S.,Horwitz E.M., Adverse events reported by patients with cancer after administration of a 2-dose mrna covid-19 vaccine. J Natl Compr Canc Netw. 20(2): 160-166, 2022. https://www.ncbi.nlm.nih.gov/pubmed/35130494.

Vapiwala N., Wong J.K., Handorf E., Paly J., Grewal A., Tendulkar R., Godfrey D., Carpenter D., Mendenhall N.P., Henderson R.H., Stish B.J., Vargas C., Salama J.K., Davis B.J.,Horwitz E.M., A pooled toxicity analysis of moderately hypofractionated proton beam therapy and intensity modulated radiation therapy in early-stage prostate cancer patients. Int J Radiat Oncol Biol Phys. 110(4): 1082-1089, 2021. https://www.ncbi.nlm.nih.gov/pubmed/33539968.

Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM. Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology:Jco1802158, 2019. PubMed

Martin, J.M., Li, T., Johnson, M.E., Murphy, C.T., Howald, A.G., Smaldone, M.C., Kutikov, A., Chen, D.Y., Viterbo, R., Greenberg, R.E., Uzzo, R.G., Horwitz, E.M. Use of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer Center.  J Natl Compr Canc Netw  13:  525-30; 2015. PubMed

Horwitz, E.M. and Weinberg, D.S.  Medicare physician payment data: Is this transparency?  Ann. Int. Med.  161(4):  291-292; 2014. PubMed

Horwitz EM. ABS brachytherapy consensus guidelines. Brachytherapy. 11(1):  4-5, 2012. PubMed

Davis BJ, Horwitz EM, Lee WR, Crook, J. M.; Stock, R. G.; Merrick, G. S.; Butler, W. M.; Grimm, P. D.; Stone, N. N.; Potters, L.; Zietman, A. L.; Zelefsky, M. J.  American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy.  Brachytherapy 11(1):6-19, 2012. PubMed

Crook, J.M.; O'Callaghan, C.J.; Duncan, G.; Dearnaley, D.P.; Higano, C.S.; Horwitz, E.M.; Frymire, E.; Malone, S.; Chin, J.; Nabid, A.; Warde, P.; Corbett, T.; Angyalfi, S.; Goldenberg, S.L.; Gospodarowicz, M.K.; Saad, F.; Logue, J.P.; Hall, E.; Schellhammer, P.F.; Ding, K.; Klotz, L.  Intermittent androgen suppression for rising PSA level after radiotherapy.  New England Journal of Medicine 367:  895-903; 2012. PubMed

Rosenthal, S.A.; Bittner, N.H.; Beyer, D.C.; Demanes, D.J.; Goldsmith, B.J.; Horwitz, E.M.; Ibbott, G.S.; Lee, W.R.; Nag, S.; Suh, W.W.; Potters, L.  American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer.  International Journal of Radiation Oncology Biology Physics 79:  335-41; 2011.  PubMed

Horwitz, E.M.  Why External Beam Radiotherapy Is Treatment of Choice for Most Men With Early-stage Nonmetastatic Prostate Cancer.  Urology 73:  470-472; 2009. PubMed

... Expand

Additional Publications

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...